Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Medicine

Background:

• Non-ST elevation acute coronary syndrome (NSTE-ACS) management often involves percutaneous coronary intervention (PCI).
• Bare-metal stents (BMS) are a common treatment, but in-stent restenosis remains a concern.
• Drug-eluting balloons (DEB) offer a localized drug delivery approach to mitigate restenosis.

Purpose of the Study:

• To compare the efficacy of a combination therapy (BMS + DEB) versus BMS alone in patients with NSTE-ACS undergoing PCI.
• To evaluate key angiographic and clinical endpoints, including in-stent restenosis (ISR), late lumen loss (LLL), and major adverse cardiac events (MACE).

Main Methods:

• A randomized controlled trial involving 85 patients with NSTEMI or UA.
• Patients were assigned to either BMS alone or BMS + DEB.
• Angiographic follow-up at 6 months assessed primary endpoints: binary ISR and LLL. Secondary endpoints included target lesion revascularization (TLR), stent thrombosis (ST), and new acute coronary syndrome (ACS).

Main Results:

• No significant difference in binary in-stent restenosis (ISR) between the BMS and BMS+DEB groups (p=0.593).
• Significantly lower late lumen loss (LLL) was observed in the BMS+DEB group compared to BMS alone (p=0.002).
• Major adverse cardiac events (MACE) rates were similar between groups (29.5% vs 24.4%, p=0.835). One case of subacute stent thrombosis occurred in the BMS+DEB group.

Conclusions:

• The combination of BMS and DEB significantly reduces late lumen loss in NSTE-ACS patients undergoing PCI.
• Despite improved angiographic parameters (reduced LLL), the BMS+DEB strategy did not demonstrate a significant improvement in clinical outcomes compared to BMS alone at 6-month follow-up.
• Further research may be warranted to explore long-term clinical benefits and patient selection for BMS+DEB therapy.